Form 4: Starovasnik Sells Twist Bioscience Shares

Melissa A. Starovasnik, a Director at Twist Bioscience Corp, reported a transaction involving the sale of 1,000 shares of common stock on April 1, 2026, executed under a pre-established Rule 10b5-1 trading plan.

Summary

• Director Melissa A. Starovasnik of Twist Bioscience Corp (TWST) sold 1,000 shares of common stock on April 1, 2026.
• The sale was conducted under a Rule 10b5-1 trading plan adopted on November 22, 2025.
• Following this transaction, Starovasnik beneficially owns 25,722 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to an insider sale, though the execution via a Rule 10b5-1 plan mitigates significant concern.

Negatives

• A director has sold a portion of their holdings in the company.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider sales, particularly when executed under a Rule 10b5-1 plan, are common and often pre-scheduled. While any sale by a director can be perceived negatively, the use of a 10b5-1 plan suggests the sale was planned in advance and not necessarily a reflection of current negative sentiment about the company's prospects.

Stakeholder Impact

• Shareholders may view the sale by a director with caution, although the pre-planned nature of the transaction under a Rule 10b5-1 plan may temper concerns.

Key Dates

Keywords

Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Twist Bioscience, TWST, Director Transaction